New combo aims to stop nausea in breast cancer patients
NCT ID NCT07254416
First seen Dec 16, 2025 · Last updated Jun 20, 2026 · Updated 26 times
Summary
This study tests whether a combination of two anti-nausea drugs (NEPA plus megestrol acetate) works better than the standard regimen (NEPA plus dexamethasone) for preventing nausea and vomiting in breast cancer patients receiving T-DXd therapy. 120 participants will be randomly assigned to one of the two groups. The goal is to improve quality of life and help patients stay on their cancer treatment without dose reductions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NEPA (netupitant/palonosetron), megestrol acetate, dexamethasone
What this could lead to
If successful, this could offer a better way to prevent nausea and vomiting in breast cancer patients on T-DXd, improving quality of life and reducing treatment interruptions.
What could go wrong
This is a small, early-stage trial (Phase 4) with only 120 participants. The new combination may not be more effective than the standard regimen, and side effects from the drugs themselves are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.